Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M2,390Revenue (TTM) $M134Net Margin (%)-89.4Altman Z-Score2.7
Enterprise Value $M2,329EPS (TTM) $-0.9Operating Margin %-73.3Piotroski F-Score2
P/E(ttm)--Beneish M-Score-4.0Pre-tax Margin (%)-88.5Higher ROA y-yN
Price/Book41.510-y EBITDA Growth Rate %1.4Quick Ratio3.9Cash flow > EarningsY
Price/Sales16.45-y EBITDA Growth Rate %9.6Current Ratio4.1Lower Leverage y-yY
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-42.5Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)--Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M142ROIC % (ttm)--Gross Margin Increase y-yN

Gurus Latest Trades with HALO

Number of guru portfolios checked: 68.
Ticker Guru Date Action
Impact Price Range
Current Price Change from Average Comment Current Shares

HALO is held by these investors:

HALO: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Stelzer LaurieCFO 2015-08-20Buy10,000$17.24-2.32view
Stelzer LaurieCFO 2015-08-20Buy10,000$17.24-2.32view
Kelley Kenneth JDirector 2015-06-18Sell20,000$21-19.81view
Kelley Kenneth JDirector 2015-03-05Sell40,000$15.339.85view
RAMSAY DAVID AVP and CFO 2014-09-16Buy25,000$8.989.21view
Torley HelenPresident and CEO 2014-09-16Buy50,000$8.9288.79view
PATTON JOHN STUARTDirector 2014-08-19Sell75,000$9.9669.08view
Engler RobertDirector 2014-08-14Sell35,000$9.9669.08view
Engler RobertDirector 2014-05-15Sell126,700$7.56122.75view
PATTON JOHN STUARTDirector 2013-09-16Sell75,000$9.1384.45view

Quarterly/Annual Reports about HALO:

News about HALO:

Articles On GuruFocus.com
Halozyme Up After Cancer Deal, Markets Down Sep 14 2017 
Halozyme Increases 2017 Financial Guidance Sep 14 2017 
Halozyme Licenses New Enhanze Target For $30 Million Upfront Payment, Future Milestones And Royaltie Sep 14 2017 
Halozyme Therapeutics To Present At Upcoming Healthcare Conferences Aug 25 2017 
Halozyme Reports Second Quarter 2017 Results Aug 08 2017 
Halozyme Therapeutics To Present At Upcoming Healthcare Conference Aug 04 2017 
Initiation Of Clinical Trial Collaboration Evaluating Halozyme's PEGPH20 In Combination With Anti-PD Jul 13 2017 
Halozyme To Host Second Quarter 2017 Financial Results Conference Call Jul 10 2017 
FDA Approves Genentech's RITUXAN HYCELA, A Subcutaneous Rituximab Coformulated With Halozyme ENHANZE Jun 22 2017 
Halozyme Phase 2 Data In Advanced Pancreas Cancer Featured In An Oral Presentation At ASCO Jun 04 2017 

More From Other Websites
No related articles found.

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat